Clinical Practice Guidelines - Resource Library-Central Precious Puberty

Video Transcription

Video Summary

This presentation introduced a newly published clinical practice guideline on central precocious puberty (CPP), developed by an international panel using GRADE methodology. CPP is defined as pubertal development before age 8 in girls and before age 9 in boys, due to premature activation of the hypothalamic-pituitary-gonadal axis. The guideline focused on key diagnostic and treatment questions, emphasizing patient-important outcomes and balancing benefits, harms, costs, feasibility, and equity.<br /><br />Several case-based recommendations were highlighted. For girls age 7 to 8 with isolated breast development, the panel suggests 4 to 6 months of observation rather than immediate testing. If puberty appears to be progressing, initial evaluation should include a basal ultrasensitive LH level rather than jumping straight to a GnRH stimulation test. Routine brain MRI is not recommended for girls ages 6 to 8 or boys ages 8 to 9 without CNS symptoms. Routine genetic testing is also not advised, though it may be considered in familial cases.<br /><br />For treatment, GnRH agonists remain first-line therapy for rapidly progressive CPP, but benefits in adult height may be modest in some children. If treatment is chosen, longer-acting formulations can be started directly; routine biochemical monitoring is not recommended, and clinical follow-up is usually sufficient. The guideline also suggests against routine addition of growth hormone and recommends stopping GnRH agonist therapy around ages 10 to 11 in girls and 11 to 12 in boys.<br /><br />The panel noted limitations, especially the lack of randomized trials and the predominance of studies in girls, and called for more research on long-term outcomes, psychosocial effects, and treatment timing.

Keywords

central precocious puberty

CPP guideline

GRADE methodology

hypothalamic-pituitary-gonadal axis

basal ultrasensitive LH

GnRH stimulation test

brain MRI

genetic testing

GnRH agonists

adult height

clinical follow-up

pubertal development


EndoCareers \| Contact Us \| Privacy Policy \| Terms of Use	CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.	2055 L Street NW, Suite 600 \| Washington, DC 20036 202.971.3636 \| 888.363.6274